For instance, Zhu et al. reported that the combination of CYP1B1 inhibitor and the anti-cancer drug paclitaxel prevented the proliferation of epithelial ovarian cancer cells in vitro and in vivo, indicating that CYP1B1 enhances the chemoresistance of ovarian cancer [38]. This evidence concerns the gene CYP1B1 and ovarian carcinoma.